Exosomal microRNA in serum is a prognostic factor in cutaneous squamous cell carcinoma.

Abstract

e22073 Background: Functional microRNA(miRNAs) is located in the area of the gene related to cancer, such as inside of oncogenes and tumor suppressor genes, loss of heterozygocity or fragile site. There are many studies show that abnormal increase expression of miRNAs when cancer occurs. While some miRNAs commonly suppress abnormal expression of tumors, they can also infer the orgin of tumor tissues because they are more often representative of unique miRNA depending on type of tumor. In many case, the miRNAs expression patterns provide more characteristic information about tumors than messenger RNA expression profinling. The miRNAs expression patterns, which have changed with tumor types, provide clue that can serve as a biological markers for diagnosis, determining the outcome of disease, and predicting treatment responses. Indeed, several studies have reported thatextracellular miRNA is related to the prognosis of disease in some cancers, such as colon cancer and breast cancer. However, so far, there is no study that has been no defenitive study on how exosomal miRNAsare related to progrosis in cutaneous squamous cell carcinoma. We studied the association between the patient’s prognosis and miRNAs detected in cancer tissue and blood serum. Methods: We analyzed 35 patients who have various stage of cutaneous squamous cell carcinoma. Cancer tissue and serum samples were sequentially obtained. The miRNAs were prified from serum exosome and cancer tissues, and miRNAs sequencing was performed. The miRNAs expression profiles and copy number variations were observed using next generation sequencing (Hiseq, illumina inc) in 35 cancer tissues and serum samples. We validated miRNAs change and patient’s prognosis. Results: miR-142-5p cluster expression level in serum exosome and cancer tissue was most correlated with poor prognosis of cutaneous squamous cell carcinoma. Exosomal miR-142-5p expression level in serum were significantly higher(P < 0.01) in patients with late stage than in patients with early stage. Also, the patients with recurrence showed high level of miR-142-5p. Conclusions: miR-142-5p expression level may be an important marker for predicting the patient’s prognosis and deciding whether undergo additional systemic chemotherapy after surgery.